Nasdaq
$2.55▼ 2.49%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $25.4MShares out 10.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.9Pre-market26.10.09 21:158-KKey event#●●●#●●●
ATOSSA THERAPEUTICS, INC.
Atossa Therapeutics has entered into a Stapled Contingent Value Rights (CVR) Agreement, entitling shareholders to 25% of the net proceeds from the potential sale or monetization of its first FDA priority review voucher. Shareholders of record as of October 19, 2026, will receive one CVR per share, subject to a $50 million aggregate payment cap. The CVRs are stapled to the common stock and cannot be traded separately until detached by the Board.…more
$2.55-2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 21:008-KKey event
ATOSSA THERAPEUTICS, INC.
Atossa Therapeutics has approved a plan to issue a contingent value right (CVR) to shareholders, allowing them to participate in 25% of the net proceeds from the monetization of its first qualifying rare pediatric disease priority review voucher, capped at $50 million. The CVRs will be attached to each share of common stock and will not trade separately.…more
$2.55-2.49%vs prev closeView filingShare - 9.18After-hours26.09.19 06:008-KKey event
ATOSSA THERAPEUTICS, INC.
Atossa Therapeutics released an updated corporate presentation on September 18, 2026, detailing the clinical and regulatory strategy for its lead program, (Z)-Endoxifen. As of June 30, 2026, the company reported $26.1 million in cash and equivalents with no outstanding debt. The company also raised $4.0 million in a June registered direct offering and expects up to $12 million in additional proceeds from the exercise of Series A and short-term Series B warrants.…more
$2.55-2.49%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.19 21:10#●●●
Atossa Therapeutics Confirms CVR Distribution Effective October 19
Atossa Therapeutics announced that shareholders of record as of October 19 will receive one Contingent Value Right (CVR) per share. These CVRs will remain stapled to the common stock and will not trade separately until the board decides otherwise.…more
$2.55-2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.9Pre-market26.10.09 21:03
●●●●●●●● ●●●●● ●●●●●●
Atossa Therapeutics has entered into a definitive agreement to implement its previously announced contingent value rights (CVR) plan. The company will distribute one CVR for each share of common stock held as of the record date.…more
$2.55-2.49%vs prev closeShareBenzinga - 7.23Regular26.07.24 01:59
●●●●●●●● ●●●●● ●●●●●●
아토스가 미 국방부의 CMMC 2.0 레벨 2 인증을 획득하며 민감 정보 보호 역량을 입증했습니다. 이는 향후 국방 분야 사업 수주에 긍정적인 영향을 줄 것으로 예상됩니다.…more
$2.55-2.49%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report